Ann: CEO letter and Operational Update, page-12

The company has already shown successful delivery of Cre into kidney cells in-vitro, which has validated the technology in vitro.

In the announcement dated the 31/10/18 this was highlighted...

‘"Can our CPPs deliver a therapeutic cargo to a tissue/cell affected by a disease process in a manner that enables the correction of that disease’?

We will answer this question for multiple cargoes and in multiple tissues in therapeutic read-outs (both in vivo and ex vivo) in 2019."

The liver was one of the tissue/cells highlighted on page 5 in the matrix diagram and has already shown in vivo validation. And if I'm not mistaken, that was with the first generation CPPs - FPP001? 

https://phylogica.com/wp-content/uploads/2017/11/171127_Company-Presentation-AGM-2017.pdf

Yesterday's update...

"We are greatly encouraged by the in vitro (test tube) performance of our ‘second generation’ CPPs which include candidates capable of delivering 25-150 times as much cargo into a target cell when compared to the cargo alone." 

and...

"Given the extent of the outperformance of our second generation CPPs in vitro, this bodes well for our imminent therapeutic in vivo read-outs."  

and.. 

"1H2019 represents an opportunity to show that our ‘second generation’ CPPs yield meaningful in vivo read-outs, demonstrating our ability to correct human disease processes in animal models of that disease. Success in these models will propel our platform into the clinic. 

Importantly, the ‘second generation’ CPP seen in Figure 2 is very attractive in terms of its ‘druglike’ properties (toxicity, manufacturability etc.) indicating an improved probability of success innavigating the IND approval process in the event that therapeutic in vivo efficacy is established."

Tony